YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice

Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders

(2010) Christian A. Heidbreder et al.   Annals of the New York Academy of Sciences

PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats

(2010) Amanda E Higley et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Dopamine D2–D3 receptor heteromers: pharmacological properties and therapeutic significance

(2009) Roberto Maggio et al.   CURRENT OPINION IN PHARMACOLOGY

Inhibition of NAALADase by 2-PMPA attenuates cocaine-induced relapse in rats: a NAAG-mGluR2/3-mediated mechanism

(2009) Zheng-Xiong Xi et al.   JOURNAL OF NEUROCHEMISTRY

Drug seeking under a second-order schedule of reinforcement depends on dopamine D₃ receptors in the basolateral amygdala.

(2008) Patricia Di Ciano   BEHAVIORAL NEUROSCIENCE

Identification of Dopamine D1–D3Receptor Heteromers

(2008) Daniel Marcellino et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

(2008) M. Shahid et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The preferential dopamine D3 receptor antagonist S33138 inhibits cocaine reward and cocaine-triggered relapse to drug-seeking behavior in rats

(2008) Xiao-Qing Peng et al.   NEUROPHARMACOLOGY

Neuroprotective effects of atypical D1receptor agonist SKF83959 are mediated via D1receptor-dependent inhibition of glycogen synthase kinase-3β and a receptor-independent anti-oxidative action

(2007) Yang Yu et al.   JOURNAL OF NEUROCHEMISTRY